Elevation Oncology
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. They leverage their ADC expertise to advance targeted therapies, including their pipeline of novel agents such as EO-1022, a HER3 antibody-drug conjugate. The company is committed to scientific excellence and aims to provide safer and more effective treatment options for cancer patients.
Industries
Nr. of Employees
small (1-50)
Elevation Oncology
101 Federal Street, Suite 1900, Boston, MA 02110
Patents
Products
HER3-targeting antibody-drug conjugate (preclinical)
A HER3-targeting antibody-drug conjugate in preclinical development that uses site-specific glycan conjugation to attach a potent cytotoxic payload with a defined DAR, designed for HER3-expressing solid tumors.
HER3-targeting antibody-drug conjugate (preclinical)
A HER3-targeting antibody-drug conjugate in preclinical development that uses site-specific glycan conjugation to attach a potent cytotoxic payload with a defined DAR, designed for HER3-expressing solid tumors.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Preclinical oncology research and translational studies
- In vitro and in vivo efficacy testing (including PDX models)
- CMC aspects of ADC conjugation and characterization
Key Technologies
- Antibody-drug conjugates (ADCs)
- Site-specific glycan conjugation
- Drug-to-antibody ratio (DAR) quantification
- Monomethyl auristatin E (MMAE) payloads
News & Updates
Elevation Oncology will participate in upcoming investor conferences as part of their ongoing engagement with the investment community.
The company reported its financial results for Q4 and full year 2024, highlighting recent business achievements.
Elevation Oncology announced the discontinuation of EO-3021 development and is advancing EO-1022 while exploring strategic options.
The company will present preclinical data for EO-1022 at the AACR Annual Meeting 2025.
Preclinical proof-of-concept data for EO-1022 will be presented at the AACR Annual Meeting 2025.
This publication details the preclinical discovery and characterization of EO-1022, a novel HER3 ADC.
Elevation Oncology will participate in upcoming investor conferences as part of their ongoing engagement with the investment community.
The company reported its financial results for Q4 and full year 2024, highlighting recent business achievements.
Elevation Oncology announced the discontinuation of EO-3021 development and is advancing EO-1022 while exploring strategic options.
The company will present preclinical data for EO-1022 at the AACR Annual Meeting 2025.
Preclinical proof-of-concept data for EO-1022 will be presented at the AACR Annual Meeting 2025.
This publication details the preclinical discovery and characterization of EO-1022, a novel HER3 ADC.